Search
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM.
Folic acid
go.drugbank.com/drugs/DB00158ApprovedInvestigationalNutraceuticalVet approvedMore specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. … [L5744] In order to function within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF).
Mixtures: Pnv-VP-U, Formula U - TabRitiometan
go.drugbank.com/drugs/DB13267ApprovedRitiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.
Leptin
go.drugbank.com/drugs/DB05098InvestigationalThus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.
CX-717
go.drugbank.com/drugs/DB05047IllicitInvestigationalCX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
Ribociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib was approved by the FDA in March 2017 under the brand name Kisqali. … Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Chlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnSimilar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone.
Celecoxib
go.drugbank.com/drugs/DB00482ApprovedInvestigational[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.